Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and a cause of treatment resistance. Two Phase III studies evaluating custirsen in men with castrate-resistant prostate cancer (CRPC) are ongoing: the SYNERGY clinical trial - designed to evaluate an overall survival benefit for custirsen in combination with first-line docetaxel treatment, and the Prostate Cancer SATURN Trial - which will evaluate a durable pain palliation benefit in patients receiving second-line chemotherapy. Both studies are currently enrolling CRPC patients.

Phase II Data Published in Clinical Cancer Research

Data from a Phase II clinical study of custirsen in combination with docetaxel retreatment or mitoxantrone as second-line chemotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) was published in the September 1, 2011 issue of Clinical Cancer Research.

In the clinical study, custirsen combined with docetaxel retreatment resulted in overall survival of 15.8 months. When custirsen was combined with mitoxantrone, overall survival was 11.5 months. The Phase II study also evaluated pain responses in patients with mCRPC. Overall, the pain response was durable (greater than or equal to three months) in 88 percent of patients who had pain or were on opioids for pain at study entry.

"These are encouraging results because we observed durable pain responses in many patients who had di
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
(Date:7/24/2015)... , Adds integrated small molecule ... offering for chronic kidney disease and oncology patients ... and dermatology , Increases group revenue and earnings ... Company"), a leading China -based biotechnology ... products, today announced that it has acquired the entire ...
(Date:7/23/2015)... ANGELES , July 23, 2015 ImmunoCellular Therapeutics, ... to report financial results for the second quarter 2015 on ... a conference call and webcast on that day at 5:00 ... and provide a business update. The call will be hosted ...   , , , LIVE CALL: ...
(Date:7/23/2015)... ... ... Science and technology continue to improve all aspects of brain tumor care –from ... Chang, MD, director of the Division of Neuro-oncology at UC San Francisco. , Dr. ... development of new treatments and advancing strategies to minimize treatment side effects at the ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... of global climate change and population growth call for sweeping ... warns a group of prestigious scientists, including an expert in ... research team, led by Nina Federoff, science and technology adviser ... a "critical need to get beyond popular biases against the ...
... process that produces both n-type and p-type doping ... the promising material for future electronic devices. ... increase conductivity in graphene nanoribbons used for interconnects. ... to graphene and then exposing it to electron-beam ...
... , CINCINNATI , Feb. 11 Kendle ... quarter and full-year 2009 financial results after the market closes on ... call and simultaneous webcast on Thursday, Feb. 25 at ... , Conference Call Instructions , To participate in the ...
Cached Biology Technology:Dramatic changes in agriculture needed as world warms and grows, researchers say 2Single-step technique produces both p-type and n-type doping for future graphene devices 2Single-step technique produces both p-type and n-type doping for future graphene devices 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast 2Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast 3
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... very fatty beans from which oil is refined into biodiesel in ... University of Southern Denmark along with researchers from Brazil have succeeded ... be possible to alter the bean,s structure in order to get ... however shows that this may not be an easy task. ...
... researchers has used next generation sequencing to identify ... pediatric speech disorder. The findings are published in ... Journal of Neurodevelopmental Disorders http://www.jneurodevdisorders.com/content/5/1/29 . ... rare, severe speech disorder that in some patients ...
... special issue of the International Journal of Global Warming ... loss and damage from the perspective of affected people in ... how climatic stressors affect communities, what measures households take to ... they are unable to adjust sufficiently. The guest-editors, Kees ...
Cached Biology News:Proteins in one of the world's main biodiesel plants have been mapped -- and it does not look good 2Loss and damage from climate change 2Loss and damage from climate change 3
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
... Leu-CMK FLISP Assay with SR-101 ... Em=620 nm) • Accurately measure serine ... or permeabilization • B-Bridge's FLISP Kits ... serine proteases (FLISPs) to measure chymotrypsin-like ...
Biology Products: